FindTrial
Sign In

Z-206 Phase III Clinical Trial - Investigation on the remission-inducing effect in patients with Crohn's disease in active phase -

Z-206 Phase III Clinical Trial - Investigation on the remission-inducing effect in patients with Crohn's disease in active phase -

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220189
Enrollment
Unknown
Registered
2005-12-19
Start date
2005-12-19
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with Crohn's disease in active phase

Interventions

investigational material(s) Generic name etc : Z-206 INN of investigational material : Therapeutic category code : 239 Other agents affecting digestive organs Dosage and Administration for Investigat

Sponsors

Zeria Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with Crohn's disease in active phase who are defined to show CDAI of 150 or higher but less than 250, and whose lesion is mainly observed at the end of ileum or lower part.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Remission induction rate—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026